NCT04398745
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04398745
Title A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function (DREAMM12)
Acronym DREAMM12
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | GRC

Facility Status City State Zip Country Details
GSK Investigational Site Tucson Arizona 85724 United States Details
GSK Investigational Site Beverly Hills California 90211 United States Details
GSK Investigational Site Sacramento California 95817 United States Details
GSK Investigational Site Jacksonville Florida 32224-3899 United States Details
GSK Investigational Site Plantation Florida 33322 United States Details
GSK Investigational Site Chicago Illinois 60611 United States Details
GSK Investigational Site Westwood Kansas 66205 United States Details
GSK Investigational Site Baltimore Maryland 21201-1595 United States Details
GSK Investigational Site Chapel Hill North Carolina 27514 United States Details
GSK Investigational Site Portland Oregon 97239 United States Details
GSK Investigational Site The Woodlands Texas 77380 United States Details
GSK Investigational Site Athens 10676 Greece Details
GSK Investigational Site Athens 11528 Greece Details
GSK Investigational Site Singapore 119228 Singapore Details
GSK Investigational Site Singapore 169856 Singapore Details
GSK Investigational Site Busan 49241 South Korea Details
GSK Investigational Site Incheon 21565 South Korea Details
GSK Investigational Site Seoul 06351 South Korea Details
GSK Investigational Site Seoul 06591 South Korea Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field